Bone Biologics, headquartered in Burlington, Massachusetts, focuses on developing bone graft substitutes for spinal fusion using the proprietary protein NELL-1 in combination with demineralized bone matrix (DBM). The company went public on November 27, 2015, and employs two full-time staff.